MISSION
Our mission is to advance research, drug development, and possible treatments for GM1 Gangliosidosis, an ultra-rare lysosomal storage disease that primarily impacts babies and children.GM1 destroys the brain and spinal cord and is ultimately fatal. Our work is guided by the belief that all those suffering from this horrendous disease deserve treatment. Treatments and discoveries associated with rare diseases can contribute to advancements with broad ramifications to the entire field of medicine.
ORGANIZATION OVERVIEW
The Cure GM1 Foundation was founded in April of 2015. To date, the primary focus of research has been the development of AAV gene therapy and small molecules. Prior to the existence of Cure GM1, there were no clinical trials even though the disease was first discovered in 1968. Advocacy, awareness, fundraising, and support of research and drug development have helped advance progress towards possible treatments.
OUR PROGRAM
To date, the primary source of funds has been individual donors via grassroots fundraising. Cure GM1 hosts an annual conference and several annual fundraisers and awareness events. Cure GM1 is in contact with the largest number of patients suffering from GM1 gangliosidosis of any entity worldwide. Cure GM1 is currently collaborating with multiple entities on research programs and has supported multiple newborn screening research projects. Recent initiatives also include medical records collection, a caregiver preferences study, and engagement with the FDA.
COMMUNICATIONS, OUTREACH, DEVELOPMENT POSITION
Skills & Experience
Candidates must demonstrate the following:
Additional candidate qualifications include:
401k
Sick time
List of paid holidays
Excellent English
To Apply
Please upload a resume and thoughtful cover letter. We will only contact candidates chosen for further consideration. No phone inquiries please. Email info@curegm1.org